<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117458</article-id><article-id pub-id-type="publisher-id">ACM-44048</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_10331375.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  甲状腺激素与急性缺血性脑卒中预后相关性的研究进展
  Research Progress on the Correlation between Thyroid Hormone and Prognosis of Acute Ischemic Stroke
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>小艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>艺东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院神经内科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3158</fpage><lpage>3167</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  甲状腺激素与急性缺血性脑卒中患者的预后密切相关，甲状腺激素作为新的预测因子，可以为急性缺血性脑卒中患者的预后提供监测指标，故本文围绕急性缺血性脑卒中患者体内甲状腺激素的变化情况、以及FT3、FT4、TT3、FT3/FT4、TSH对急性缺血性脑卒中患者预后的影响和补充甲状腺激素对预后的影响的研究进展加以综述，旨在为相关研究提供理论基础。
   Thyroid hormone is closely related to the prognosis of patients with acute ischemic stroke. As a new predictor, thyroid hormone can provide a monitoring index for the prognosis of patients with acute ischemic stroke. Therefore, this paper reviews the changes of thyroid hormone in patients with acute ischemic stroke, the effects of FT3, FT4, TT3, FT3/FT4 and TSH on the prognosis of patients with acute ischemic stroke, and the effects of thyroid hormone supplementation on the prognosis, aiming to provide a theoretical basis for related studies.
 
</p></abstract><kwd-group><kwd>甲状腺激素，急性缺血性脑卒中，预后, Thyroid Hormone</kwd><kwd> Acute Ischemic Stroke</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>甲状腺激素与急性缺血性脑卒中患者的预后密切相关，甲状腺激素作为新的预测因子，可以为急性缺血性脑卒中患者的预后提供监测指标，故本文围绕急性缺血性脑卒中患者体内甲状腺激素的变化情况、以及FT3、FT4、TT3、FT3/FT4、TSH对急性缺血性脑卒中患者预后的影响和补充甲状腺激素对预后的影响的研究进展加以综述，旨在为相关研究提供理论基础。</p></sec><sec id="s2"><title>关键词</title><p>甲状腺激素，急性缺血性脑卒中，预后</p></sec><sec id="s3"><title>Research Progress on the Correlation between Thyroid Hormone and Prognosis of Acute Ischemic Stroke<sup> </sup></title><p>Xiaoyan He, Yidong Xue</p><p>Department of Neurology, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/39-1572364x4_hanspub.png?20210723082946485" /></p><p>Received: Jun. 19<sup>th</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/39-1572364x5_hanspub.png?20210723082946485" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Thyroid hormone is closely related to the prognosis of patients with acute ischemic stroke. As a new predictor, thyroid hormone can provide a monitoring index for the prognosis of patients with acute ischemic stroke. Therefore, this paper reviews the changes of thyroid hormone in patients with acute ischemic stroke, the effects of FT3, FT4, TT3, FT3/FT4 and TSH on the prognosis of patients with acute ischemic stroke, and the effects of thyroid hormone supplementation on the prognosis, aiming to provide a theoretical basis for related studies.</p><p>Keywords:Thyroid Hormone, Acute Ischemic Stroke, Prognosis</p><disp-formula id="hanspub.44048-formula27"><graphic xlink:href="//html.hanspub.org/file/39-1572364x6_hanspub.png?20210723082946485"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1572364x7_hanspub.png?20210723082946485" /> <img src="//html.hanspub.org/file/39-1572364x8_hanspub.png?20210723082946485" /></p></sec><sec id="s5"><title>1. 引言</title><p>急性缺血性脑卒中发生后机体通过调节下丘脑–垂体–甲状腺轴而引起甲状腺激素代谢异常，同时急性缺血性脑卒中患者体内甲状腺激素的变化对其预后具有一定的影响。本文通过结合国内外文献，主要从以下几方面展开：(1) 急性缺血性脑卒中对甲状腺激素的影响：包括急性缺血性脑卒中患者体内甲状腺激素水平的变化及其原因；(2) 甲状腺激素对急性缺血性脑卒中的影响：包括甲状腺激素变化对急性缺血性脑卒中患者预后的影响及其作用机制；(3) 补充甲状腺激素对急性脑卒中患者预后的研究进展及补充甲状腺激素对急性脑卒中患者预后影响的作用机制。就目前关于甲状腺激素与急性缺血性脑卒中预后的相关性研究现状进行了总结，并为以后研究补充甲状腺激素对急性缺血性脑卒中患者预后影响的具体机制提供研究方向。</p></sec><sec id="s6"><title>2. 甲状腺激素</title><p>甲状腺在TSH刺激下合成并释放甲状腺激素，主要包括T3和T4，血液循环中部分T4在脱碘酶作用下转化为T3，且T3的活性是T4的3~5倍，外周血中T3和T4主要以游离形式和结合形式存在，且以游离形式结合靶细胞发挥生物学作用 [<xref ref-type="bibr" rid="hanspub.44048-ref1">1</xref>]。</p></sec><sec id="s7"><title>3. 急性缺血性脑卒中对甲状腺激素的影响</title><sec id="s7_1"><title>3.1. 急性缺血性脑卒中患者体内甲状腺激素水平的变化</title><p>急性缺血性脑卒中发生后机体出现神经功能缺陷的同时发生内分泌及代谢变化，研究表明，AIS患者甲状腺激素代谢异常，主要表现如下：(1) 单纯T3下降，包括总三碘甲状腺原氨酸(TT3)、FT3下降，不伴T4或TSH改变；(2) 伴TSH下降：FT3下降伴TSH下降，TT3下降伴TSH下降，总甲状腺素(TT4)下降伴TSH下降；(3) 伴TSH升高：T3、FT3下降伴TSH升高，TT3、FT3下降伴TSH升高 [<xref ref-type="bibr" rid="hanspub.44048-ref1">1</xref>]。急性缺血性脑卒中可引起正常甲状腺病态综合征(ESS)，其主要临床特点为甲状腺激素水平异常，但甲状腺功能正常，包括低T3综合征、低T3和T4综合征、高T4综合征等，其中低T3综合征最为常见，表现为血清T3或FT3水平降低、T4降低或正常、TSH正常。近年越来越多研究证实，ESS可发生于AIS及其他危重病患者，并对AIS患者预后具有重要预测价值 [<xref ref-type="bibr" rid="hanspub.44048-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref3">3</xref>]。</p></sec><sec id="s7_2"><title>3.2. 急性缺血性脑卒中患者体内甲状腺激素水平变化的原因</title><sec id="s7_2_1"><title>3.2.1. 应激状态</title><p>急性缺血性脑卒中患者皮质醇、糖皮质激素分泌增加，下丘脑–垂体–甲状腺轴活性受到抑制，T4分泌减少，外周组织T4向T3转化途径发生障碍，进而导致血清T3水平下降 [<xref ref-type="bibr" rid="hanspub.44048-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref4">4</xref>]。<sup> </sup></p></sec><sec id="s7_2_2"><title>3.2.2. 下丘脑–垂体功能紊乱</title><p>(1) 急性缺血性脑卒中患者脑组织缺血、缺氧及水肿使组织中5’-脱碘酶活性降低，抑制T4向T3转化，进而使血清T3水平及脑组织对T3的反应性降低；而这种低T3的状态可以降低机体的基础代谢率。(2) 急性缺血性脑卒中病情严重时脑水肿导致颅内压升高，中线结构移位，脑组织压迫下丘脑–垂体。导致其分泌功能紊乱，垂体对血液中T3、T4水平低下时的正反馈调节作用减弱 [<xref ref-type="bibr" rid="hanspub.44048-ref5">5</xref>]。<sup> </sup></p></sec><sec id="s7_2_3"><title>3.2.3. 机体代谢变化</title><p>急性缺血性脑卒中患者出现一过性低蛋白血症时机体合成甲状腺结合球蛋白减少，甲状腺激素抑制物水平升高，甲状腺激素代谢发生障碍，进而导致甲状腺激素水平改变，引起低T3 [<xref ref-type="bibr" rid="hanspub.44048-ref6">6</xref>]。<sup> </sup></p></sec><sec id="s7_2_4"><title>3.2.4. 细胞因子参与</title><p>严重的急性缺血性脑卒中还会使多种细胞因子分泌异常，如白介素6 (IL-6)、肿瘤坏死因子α (TNF-α)等释放入血，可能导致CRP升高以及抑制了下丘脑–垂体–甲状腺轴活性，减弱了TSH对促甲状腺激素释放激素的应答反应，进而导致TSH分泌减少和甲状腺功能减弱 [<xref ref-type="bibr" rid="hanspub.44048-ref7">7</xref>]。但在严重急性脑卒中患者中，低T3和炎症标志物升高之间的联系可能有助于解释这些患者低血清T3的病理生理学 [<xref ref-type="bibr" rid="hanspub.44048-ref3">3</xref>]。</p></sec></sec></sec><sec id="s8"><title>4. 甲状腺激素对急性缺血性脑卒中的影响</title><p>入院24小时及72小时急性缺血性脑卒中患者血清TSH水平升高可以抑制甲状腺功能，处于低代谢状态，有利于降低机体代谢及耗氧量，有助于损伤部位的恢复 [<xref ref-type="bibr" rid="hanspub.44048-ref8">8</xref>]。但异常的甲状腺激素变化对急性缺血性脑卒中患者的预后具有一定的影响。</p><sec id="s8_1"><title>4.1. 甲状腺激素变化对急性脑卒中患者预后的影响</title><sec id="s8_1_1"><title>4.1.1. FT3</title><p>FT3水平与急性缺血性脑卒中患者预后不良的风险之间存在负相关，预后不良的患者FT3较低；入院时FT3值较低与急性脑卒中患者3个月的功能结局和死亡率较低相关 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>]。研究发现较低的FT3值与出院时较差的功能结果相关。此外，FT3值对预后的不利影响随着FT3值的降低而增加 [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>]。有研究观察到FT3，而不是FT4或TSH，与较差的功能预后独立相关。在没有原发性甲状腺疾病的情况下，急性疾病可导致外周FT4转化为FT3的减少，这表明FT3对危重疾病的影响可能比FT4、TSH和总甲状腺激素组分更敏感。有ROC分析显示，预测不良出院结局的临界值为2.29 pg/mL，处于正常参考范围的下限 [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>]。有研究结果显示，血清TSH、FT3水平是急性缺血性脑卒中患者短期(14天)预后的独立影响因素，且TSH联合FT3对急性缺血性脑卒中患者短期(14天)预后的预测效能较高 [<xref ref-type="bibr" rid="hanspub.44048-ref1">1</xref>]。而在临床甲状腺功能正常的急性缺血性脑卒中患者中，初始T3/FT3低可能与更差的结果相关 [<xref ref-type="bibr" rid="hanspub.44048-ref12">12</xref>]。<sup> </sup></p></sec><sec id="s8_1_2"><title>4.1.2. FT4</title><p>FT4水平与急性缺血性脑卒中患者预后不良的风险呈正相关，预后不良的患者FT4较高 [<xref ref-type="bibr" rid="hanspub.44048-ref13">13</xref>]。<sup> </sup></p></sec><sec id="s8_1_3"><title>4.1.3. TT3</title><p>TT3水平和急性缺血性脑卒中患者不良预后风险之间的呈负相关，预后不良的患者TT3较低 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]。有研究显示，在65岁或65岁以上的患者中，较低的T3总浓度是急性缺血性脑卒中后功能不良预后的独立预测因素 [<xref ref-type="bibr" rid="hanspub.44048-ref14">14</xref>]。研究表明，较低的T3总水平(入院时仍在正常范围内)也与较大的临床严重程度相关，与脑卒中后功能不良预后独立相关 [<xref ref-type="bibr" rid="hanspub.44048-ref15">15</xref>]。</p></sec><sec id="s8_1_4"><title>4.1.4. FT3/FT4比值</title><p>预后不良的患者FT3/FT4比值较低 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]。<sup> </sup></p></sec><sec id="s8_1_5"><title>4.1.5. TSH</title><p>在参考范围内较低的TSH水平与负面的临床结果相关 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]，初始TSH (临床或亚临床甲状腺功能减退)升高可能对应更好的功能结果 [<xref ref-type="bibr" rid="hanspub.44048-ref12">12</xref>]。</p><p>总之，急性缺血性脑卒中患者FT3、TT3和FT3/FT4比值明显较低，但FT4水平较高与预后不良相关。T3和T4具有相似的化学结构和生物功能，有研究分析，它们显示出与中风预后相反的相关性。在外周血中，大多数T3 (80%~90%)是通过脱碘酶从T4转化而来的。在临床应激状态下，这种转化被抑制。因此，T3的水平下降，而T4的水平上升。T3的活性是T4的三到五倍，因此T3是发挥广泛生物学作用的主要甲状腺激素，包括对神经系统的影响。因此，在急性缺血性脑卒中中，T3水平的下降可能是影响卒中预后的主要因素 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]。</p></sec></sec><sec id="s8_2"><title>4.2. 甲状腺激素变化对急性脑卒中患者预后影响的作用机制</title><sec id="s8_2_1"><title>4.2.1. 低FT3降低急性缺血性脑卒中的神经保护、增加继发性脑损伤</title><p>有试验发现，在大鼠脑缺血/再灌注模型中，外源性T3和T4提高了神经保护剂脑源性神经营养因子(BDNF)和胶质细胞源性神经营养因子(GDNF)的浓度。也有试验研究结果表明，在短暂大脑中动脉闭塞(t-MCAO)雄性小鼠模型中，注射T3可通过抑制微血管周围星形细胞末足中水通道蛋白-4 (AQUP 4)的表达来减轻梗死及相关水肿 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref17">17</xref>]。抑制AQP4基因表达可能是T3抗水肿活性的机制之一 [<xref ref-type="bibr" rid="hanspub.44048-ref18">18</xref>]。在脑缺血动物模型中，T3和T4可通过刺激星形胶质细胞脂肪酸氧化来抑制凋亡、抵抗兴奋性相关氨基酸毒性、抑制炎症反应和增加ATP产生 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]，改善创伤性脑损伤后的继发性脑损伤。因此推测，低FT3患者在急性缺血性脑卒中后会经历神经保护降低和继发性脑损伤，导致较差的预后 [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>]。</p></sec><sec id="s8_2_2"><title>4.2.2. 低FT3增加谷氨酸盐的释放</title><p>一项研究观察到，在手术或化学性甲状腺功能减退的急性缺血性脑卒中沙鼠中，谷氨酸盐的释放增加，谷氨酸盐会对脑组织产生毒性 [<xref ref-type="bibr" rid="hanspub.44048-ref9">9</xref>]。有体外研究报道T3通过转录和非转录机制对神经元和胶质细胞的谷氨酸毒性发挥保护作用 [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref18">18</xref>] 这一机制可以解释急性缺血性脑卒中预后不良和患者血清FT3水平低之间的关系。</p></sec><sec id="s8_2_3"><title>4.2.3. 低FT3抑制急性缺血性脑卒中后内源性脑修复系统</title><p>中风后内源性大脑修复机制的下调。梗死周围区模拟了大脑发育的早期阶段，具有较强的可塑性和一个允许重塑的微环境 [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>]。T3对于新神经元的产生和成熟以及轴突髓鞘形成尤为重要 [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>]。因此推测，FT3水平较低的患者可能会在急性缺血性脑卒中后内源性脑修复系统受到抑制，从而导致较差的功能预后 [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>]。</p></sec></sec></sec><sec id="s9"><title>5. 补充甲状腺激素对急性脑卒中患者预后的研究进展</title><p>(1) T3和T2：有研究已经证实甲状腺激素T3以溶液或纳米颗粒配方给予时，具有神经保护和抗水肿活性。也有研究分别使用了短暂性大脑中动脉闭塞(t-MCAO)和永久性(p-MCAO)模型来研究缺血性脑卒中。在脑卒中t-MCAO模型中观察到组织梗死显著减少，水肿同时减少；然而，在p-MCAO模型中，没有观察到T3的益处。T3对t-MCAO小鼠的神经功能有显著改善。此外，有研究还检测了T3天然去碘代谢产物T2在脑卒中MCAO模型中的作用。T2能有效减小梗死面积和水肿的形成。这些研究为促进急性缺血性脑卒中甲状腺激素的临床开发提供了依据 [<xref ref-type="bibr" rid="hanspub.44048-ref16">16</xref>]。<sup> </sup></p><p>总之，研究数据证明，T3对t-MCAO的神经保护作用可转化为功能结果的改善。动物急性缺血性脑卒中模型研究表明，T3对急性缺血性脑卒中患者有治疗作用，通过增加神经营养因子，体外降低炎症反应，恢复神经营养因子表达，使神经功能得到改善 [<xref ref-type="bibr" rid="hanspub.44048-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref19">19</xref>]。总之，研究证明了T3是关键的稳态调节机制，这对维持适当水平的兴奋和稳定神经元活动的机制至关重要，有助于大脑皮层重组和功能恢复 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。研究发现T2在缺血性脑卒中小鼠模型中具有较强的神经保护和抗水肿活性，疗效优于T3，同时T2比T3的甲状腺毒性小得多 [<xref ref-type="bibr" rid="hanspub.44048-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref21">21</xref>]。</p><p>(2) T4：Rami和Krieglstein (1992)发现，每天反复服用T4可减少缺血造成的海马神经元损伤，已知甲状腺激素支持脑血管系统的完整性。此外，T4的甲状腺素胺衍生物已被证明通过其诱导低温的能力来保护缺血性脑损伤 [<xref ref-type="bibr" rid="hanspub.44048-ref22">22</xref>]。</p><p>(3) TSH：SKVORTSOVA等 [<xref ref-type="bibr" rid="hanspub.44048-ref23">23</xref>] 研究结果显示，AIS后24 h内给予TSH释放激素治疗可有效提高患者甲状腺激素水平，减少低T3综合征发生率，改善NIHSS评分 [<xref ref-type="bibr" rid="hanspub.44048-ref1">1</xref>]。</p><p>TH是中风和脑损伤恢复的关键调节因子。目前仍缺乏TH促进脑卒中后功能恢复的潜在机制的证据，但有研究评估TH在缺血后脑中的作用 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。外源性补充甲状腺激素或其代谢产物在急性缺血性脑卒中小鼠模型中具有神经保护作用 [<xref ref-type="bibr" rid="hanspub.44048-ref18">18</xref>]。甲状腺激素治疗降低了大脑中动脉闭塞后的反应性胶质增生、炎症和细胞死亡，也有助于恢复神经营养蛋白的表达 [<xref ref-type="bibr" rid="hanspub.44048-ref24">24</xref>]。</p><sec id="s9_1"><title>5.1. 补充甲状腺激素对急性脑卒中患者预后影响的作用机制</title><sec id="s9_1_1"><title>5.1.1. 基因组作用机制</title><p>有研究报道了急性缺血性脑卒中患者恢复的关键T3机制。考虑到T3在大脑中的基因组作用主要通过与TRα1和TRβ1结合介导 [<xref ref-type="bibr" rid="hanspub.44048-ref25">25</xref>]，研究评估了它们在缺血后小鼠大脑中的水平和表达模式。一项研究报告在永久性中脑闭塞(MCAO) [<xref ref-type="bibr" rid="hanspub.44048-ref26">26</xref>] 后14天，与未受影响的梗死周围皮层和对侧半球相比，梗死核心中的TRβ1表达减少。研究还发现，与非中风患者相比，TRβ1在人脑梗死核心显著增加。综上所述，我们发现脑缺血诱导人大脑TR表达的异质性改变，这可能暗示着T3信号通路的重要作用。有研究在细胞质中也发现了TRα1和TRβ1，这可能增加T3细胞核的输入 [<xref ref-type="bibr" rid="hanspub.44048-ref27">27</xref>]。与MCAO [<xref ref-type="bibr" rid="hanspub.44048-ref27">27</xref>] 术后14天的研究结果一致，TRα1和TRβ1在神经元和胶质瘢痕反应性星形胶质细胞的胞浆中均有异质表达。然而，在na&#239;ve鼠脑 [<xref ref-type="bibr" rid="hanspub.44048-ref28">28</xref>] 中阳性的GFAP星形胶质细胞中没有发现TR亚型。如果TR表达对胶质瘢痕的形成和功能有影响，则应作为后续研究的主题。</p></sec><sec id="s9_1_2"><title>5.1.2. 神经元重组机制</title><p>当发生急性脑卒中后，神经元轴突和树突棘变性，导致大脑功能丧失。发生急性脑卒中后幸存的神经元试图稳定兴奋抑制回路、以调节大脑兴奋性，研究证明T3调节可塑性机制可能作为代偿机制来确保适当的突触神经传递 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。树突棘具有高度的动态性 [<xref ref-type="bibr" rid="hanspub.44048-ref29">29</xref>]，特别是卒中后，树突棘发生重组，包括棘密度增加和棘翻转 [<xref ref-type="bibr" rid="hanspub.44048-ref30">30</xref>]。我们观察到T3处理的Thy1-YFP小鼠皮质层的棘密度增加，特别是在梗死周围区域，这有助于自发恢复。我们发现在T3治疗的动物中，在梗死周围区域薄的突起密度增加，蘑菇状棘的数量增加，表明T3在数量和结构上调节了棘的重组 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。</p></sec><sec id="s9_1_3"><title>5.1.3. 神经突触前蛋白作用机制</title><p>有文章曾研究了突触前蛋白synaptophysin和synaptotagmin的水平，这两种蛋白分别调节神经递质的释放 [<xref ref-type="bibr" rid="hanspub.44048-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref33">33</xref>]，经T3处理的小鼠缺血后大脑中synaptotagmin 1和2水平的增加支持了神经递质释放概率的增加，这反过来可能增加突触效能 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。这表明T3通过调节体内稳态，以减少神经递质释放和过度兴奋。然而，T3如何激活/抑制synaptotagmin作用的突触泡仍有待阐明 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。</p></sec><sec id="s9_1_4"><title>5.1.4. 谷氨酸的突触后反应机制</title><p>神经传递的有效性还依赖于神经元末端对谷氨酸的突触后反应，这种反应可以通过改变iGluRs AMPA和NMDA的数量或功能来调节 [<xref ref-type="bibr" rid="hanspub.44048-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref35">35</xref>]。事实上，中风诱导的谷氨酸释放激活AMPA受体 [<xref ref-type="bibr" rid="hanspub.44048-ref36">36</xref>] 和NMDA受体 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]，这些变化与兴奋性突触传递和运动恢复有关。发现在T3治疗的小鼠梗死周围区域AMPA受体亚基GluR2水平增加。AMPA受体亚基GluR2调控AMPA受体功能、神经传递和突触可塑性的关键方面 [<xref ref-type="bibr" rid="hanspub.44048-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref38">38</xref>]，最终有助于缺血后大脑的兴奋性增加和恢复 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。有研究报道10 μM的T3与海马神经元 [<xref ref-type="bibr" rid="hanspub.44048-ref39">39</xref>] 的小型兴奋性突触后电流频率和谷氨酸诱导毒性的降低有关。缺血损伤后，突触谷氨酸信号也由于神经元回路的强直性抑制而受到抑制，最终限制了恢复过程 [<xref ref-type="bibr" rid="hanspub.44048-ref40">40</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref42">42</xref>]。通过刺激谷氨酸信号 [<xref ref-type="bibr" rid="hanspub.44048-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref41">41</xref>] 和减少GABA抑制 [<xref ref-type="bibr" rid="hanspub.44048-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref43">43</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref44">44</xref>] 在运动和体感皮层中调节来改变兴奋–抑制比可以加速小鼠的运动恢复。研究证实了中风啮齿动物中PV/GABA细胞的减少与功能恢复之间的相关性 [<xref ref-type="bibr" rid="hanspub.44048-ref45">45</xref>]。此外，以及短暂MCAO后静脉输注人骨髓间充质基质细胞 [<xref ref-type="bibr" rid="hanspub.44048-ref46">46</xref>] 降低了皮质PV免疫反应性或活性，并与增强丧失的神经功能恢复有关。总之，研究结果揭示了T3介导的脑卒中恢复机制的重要意义 [<xref ref-type="bibr" rid="hanspub.44048-ref20">20</xref>]。</p></sec><sec id="s9_1_5"><title>5.1.5. 海马CA1区神经营养因子作用机制</title><p>T3通过增加海马CA1区神经营养因子(BDNF、GDNF)基因表达，对缺血性脑卒中有治疗作用 [<xref ref-type="bibr" rid="hanspub.44048-ref47">47</xref>]。有研究采用tMCAo模型进行实验评价 [<xref ref-type="bibr" rid="hanspub.44048-ref48">48</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref49">49</xref>]。在急性脑缺血中，海马CA1区在短暂性脑缺血后的2~4天内发生继发性细胞死亡 [<xref ref-type="bibr" rid="hanspub.44048-ref50">50</xref>]。Genovese等人最近的研究也证实了tMCAo干扰海马CA1区神经营养因子(BDNF和GDNF)的表达。这种情况导致这些神经营养蛋白表达的严重缺陷 [<xref ref-type="bibr" rid="hanspub.44048-ref21">21</xref>]。Chen等人 [<xref ref-type="bibr" rid="hanspub.44048-ref51">51</xref>] 在一篇综述文章中指出，BDNF是一种安全、潜在的抗缺血性脑损伤的神经保护药物。Duarte等 [<xref ref-type="bibr" rid="hanspub.44048-ref52">52</xref>] 研究了GDNF在缺血脑中的神经保护作用。Sui等人 [<xref ref-type="bibr" rid="hanspub.44048-ref53">53</xref>] 证实，THs通过启动子特异性调节BDNF，增加了正常大鼠海马组织中BDNF基因的表达。Campolo等人 [<xref ref-type="bibr" rid="hanspub.44048-ref54">54</xref>] 研究表明，脑卒中后ICV注射T4可增加海马CA1区BDNF和GDNF RNA转录和蛋白水平。在类似的研究中，Genovese等研究了 [<xref ref-type="bibr" rid="hanspub.44048-ref22">22</xref>]，T4对脑卒中再灌注后缺血模型的影响。结果表明，T4通过抗凋亡和抗炎机制调节急性缺血性脑卒中大鼠脑组织中NFs (BDNF和GDNF)的表达，对脑缺血有治疗作用。本研究结果证实，T3处理的动物海马CA1神经元存活率更高，为促进临床开发T3作为缺血性脑卒中的有效治疗手段，减少认知功能障碍提供了依据 [<xref ref-type="bibr" rid="hanspub.44048-ref47">47</xref>]。</p></sec><sec id="s9_1_6"><title>5.1.6. 海马CA1区暗神经元数量变化机制</title><p>研究结果显示，脑缺血后海马CA1区暗神经元平均数量较高。与缺血组相比，T3组暗锥体神经元数量减少。Rami和Krieglstein [<xref ref-type="bibr" rid="hanspub.44048-ref47">47</xref>] 的研究表明，每天服用T4可减轻脑缺血后海马神经元的损伤。结果显示，与缺血组相比，T4组神经密度增加50%。Losi等人 [<xref ref-type="bibr" rid="hanspub.44048-ref41">41</xref>] 报道，非基因组T3给药可保护大鼠海马神经元免受谷氨酸中毒。因此，T3的非基因组和基因组机制都参与其中保护神经元和胶质细胞免受谷氨酸毒性 [<xref ref-type="bibr" rid="hanspub.44048-ref54">54</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref55">55</xref>]。</p></sec><sec id="s9_1_7"><title>5.1.7. 大脑免受缺血再灌注(I/R)损伤的假说机制</title><p>缺血后T4治疗可以保护大脑免受缺血再灌注(I/R)损伤的假说。主要表现为：(1) T4抗脑缺血；(2) tMCAO在缺血组织中诱导反应性胶质细胞增生，经T4 tmcao处理后，可有效减少缺血组织的反应性胶质细胞增生，(3) T4对缺血脑组织iNOS和COX-2表达的影响；(4) T4恢复了缺血脑组织中神经营养因子的表达，(5) T4给药恢复了缺血大鼠Bcl-2的表达。MCAo诱导缺血损伤大鼠Bax表达。经T4处理后，这一效果被逆转。(6) T4诱导的神经保护可能涉及p38 MAPK和PKCd通路，结果显示，MCAo诱导磷酸化p38 MAPK水平升高。T4组显著抑制p38 MAPK磷酸化。总之有研究报道，Zhang等 [<xref ref-type="bibr" rid="hanspub.44048-ref56">56</xref>] 的另一项研究提示AIS患者血清中T3水平低与神经功能不良相关。此前，Hiroi等 [<xref ref-type="bibr" rid="hanspub.44048-ref57">57</xref>] 研究发现单次注射T3可以增加脑内PI3-kinase/Akt通路活性，修复神经功能缺损评分。此外，还发现T3可通过与eNOS [<xref ref-type="bibr" rid="hanspub.44048-ref57">57</xref>] 相关的血管舒张机制降低局灶性脑缺血时的血压。因此，在脑卒中的schemial模型中T3的使用可以防止脑卒中的恶化 [<xref ref-type="bibr" rid="hanspub.44048-ref47">47</xref>]。通过不同的研究探讨THs抗缺血毒性的机制和分子基础 [<xref ref-type="bibr" rid="hanspub.44048-ref54">54</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref58">58</xref>]。此外，甲状腺激素可刺激内皮细胞，增加血管舒张因子的分泌。甲状腺激素水平与脑乙酰胆碱活性、胆碱能功能以及神经生长因子等多种神经营养因子的分泌密切相关 [<xref ref-type="bibr" rid="hanspub.44048-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44048-ref53">53</xref>]。</p></sec></sec></sec><sec id="s10"><title>6. 结论</title><p>急性缺血性脑卒中发生后机体通过调节下丘脑–垂体–甲状腺轴而引起甲状腺激素代谢异常，主要表现为正常甲状腺病态综合征(ESS)，其中，低T3综合征最为常见，急性脑卒中患者体内甲状腺激素水平变化的原因与应激状态、下丘脑–垂体功能紊乱、机体代谢变化、细胞因子参与等相关。甲状腺激素变化对急性缺血性脑卒中患者的预后存在一定的影响：(1) FT3水平与急性缺血性脑卒中患者预后不良的风险之间存在负相关；(2) FT4水平与急性缺血性脑卒中患者预后不良的风险呈正相关；(3) TT3水平和急性缺血性脑卒中不良预后风险之间呈负相关；(4) 预后不良的患者FT3/FT4比值较低；(5) 在参考范围内较低的TSH水平与负面的临床结果相关。甲状腺激素的变化可引起神经保护剂的浓度降低，微血管周围星形细胞末足中水通道蛋白-4 (AQUP 4)的表达，引起水肿，同时反应性星形胶质细胞、肥大细胞浸润和诱导型一氧化氮合酶使得脑细胞凋亡、发生炎症反应，引起创伤性脑损伤后的继发性脑损伤，释放的谷氨酸盐会引起脑组织的毒性兴奋，同时，急性脑卒中后内源性大脑修复机制的下调，导致较差的预后结果。对于急性脑卒中患者给予补充T3、T2时，具有神经保护和抗水肿活性。动物脑卒中模型研究表明，T3对缺血性脑卒中有治疗作用，通过增加神经营养因子，体外降低炎症反应，恢复神经营养因子表达，使神经功能得到改善。总之，研究证明了T3调节关键的稳态调节机制，这对维持适当水平的兴奋和稳定神经元活动的机制至关重要，有助于大脑皮层重组和功能恢复。反复服用T4可减少缺血造成的海马神经元损伤，可使神经元密度增加，具有神经保护作用，支持脑血管系统的完整性。给予TSH 释放激素治疗可有效提高患者甲状腺激素水平，减少低T3综合征发生率，改善NIHSS评分。动物研究表明，补充甲状腺激素主要与基因组作用机制、神经元重组机制、神经突触前蛋白作用机制、谷氨酸的突触后反应机制、海马CA1区神经营养因子作用机制、海马CA1区暗神经元数量变化机制、大脑免受缺血再灌注(I/R)损伤的假说机制等相关，来改善急性缺血性脑卒中患者的预后。</p><p>目前研究表明甲状腺激素与急性缺血性脑卒中患者预后存在一定的相关性，这为以后急性缺血性脑卒中患者更好的预后，提供了可观的参考价值，为临床上进一步研究急性缺血性脑卒中预后展开了一个方向。</p></sec><sec id="s11"><title>基金项目</title><p>延安市科技项目(2018CGZH-15)。</p></sec><sec id="s12"><title>文章引用</title><p>何小艳,薛艺东. 甲状腺激素与急性缺血性脑卒中预后相关性的研究进展Research Progress on the Correlation between Thyroid Hormone and Prognosis of Acute Ischemic Stroke[J]. 临床医学进展, 2021, 11(07): 3158-3167. https://doi.org/10.12677/ACM.2021.117458</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44048-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">商娜, 刘慧珍, 李芳, 刘芦姗, 王丰容, 李俊玉, 王雅慧, 李培兰, 郭树彬. 甲状腺激素水平、TOAST分型与急诊急性缺血性脑卒中患者短期预后的关系研究[J]. 实用心脑肺血管病杂志, 2020, 28(12): 40-45+51.</mixed-citation></ref><ref id="hanspub.44048-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">刘丽娜, 林财威, 王香华, 刘伟, 张飞, 王旭东. 危重症患者血清甲状腺素水平对预后的影响[J]. 中国临床医生, 2014, 42(12): 45-46.</mixed-citation></ref><ref id="hanspub.44048-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lamba, N., Liu, C., Zaidi, H., Broekman, M.L.D., Simjian, T., Shi, C., Doucette, J., Ren, S., Smith, T.R., Mekary, R.A. and Bunevicius, A. (2018) A Prognostic Role for Low Tri-Iodothyronine Syndrome in Acute Stroke Patients: A Systematic Review and Meta-Analysis. Clinical Neurology and Neurosurgery, 169, 55-63.  
&lt;br&gt;https://doi.org/10.1016/j.clineuro.2018.03.025</mixed-citation></ref><ref id="hanspub.44048-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">袁二燕, 苏艳超, 王志强. 正常甲状腺病态综合征与危重症[J]. 中国实用医药, 2015, 10(5): 77-78.</mixed-citation></ref><ref id="hanspub.44048-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">山媛, 蒋锋, 崔小丽. 血清游离甲状腺素水平与甲状腺激素水平正常的脑梗死患者颈动脉粥样硬化斑块的关系研究[J]. 实用心脑肺血管病杂志, 2018, 26(11): 37-41.</mixed-citation></ref><ref id="hanspub.44048-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">徐明然, 祝滨, 胡颖, 陈蕾, 沙霞, 王璐, 卫清琪, 姜欣, 钟琪, 孙晓江. 低三碘甲状腺原氨酸综合征与急性脑卒中的相关性[J]. 中国老年学杂志, 2016, 36(12): 2906-2907.</mixed-citation></ref><ref id="hanspub.44048-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">梁雁, 吴泳, 伍秀宇, 陈钢涛, 梁汉周, 黄丹丹. 缺血性脑卒中患者血清FT3、FT4、TSH水平变化的临床意义[J]. 中国当代医药, 2016, 23(1): 64-66+70.</mixed-citation></ref><ref id="hanspub.44048-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">李峥嵘, 刘芸芸, 季永欣. 动态检测甲状腺激素水平在急性脑卒中的应用价值[J]. 现代实用医学, 2019, 31(3): 334-336.</mixed-citation></ref><ref id="hanspub.44048-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, X., Xing, H., Wu, J., Du, R., Liu, H., Chen, J., Wang, J., Wang, C. and Wu, Y. (2017) Prognostic Value of Thyroid Hormones in Acute Ischemic Stroke—A Meta Analysis. Scientific Reports, 7, Article No. 16256.  
&lt;br&gt;https://doi.org/10.1038/s41598-017-16564-2</mixed-citation></ref><ref id="hanspub.44048-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Suda, S., Shimoyama, T., Nagai, K., Arakawa, M., Aoki, J., Kanamaru, T., Suzuki, K., Sakamoto, Y., Takeshi, Y., Matsumoto, N., Nishiyama, Y., Nito, C., Mishina, M. and Kimura, K. (2018) Low Free Triiodothyronine Predicts 3-Month Poor Outcome after Acute Stroke. Journal of Stroke &amp; Cerebrovascular Diseases, 27, 2804-2809.  
&lt;br&gt;https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.06.009</mixed-citation></ref><ref id="hanspub.44048-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Suda, S., Muraga, K., Kanamaru, T., Okubo, S., Abe, A., Aoki, J., Suzuki, K., Sakamoto, Y., Shimoyama, T., Nito, C. and Kimura, K. (2016) Low Free Triiodothyronine Predicts Poor Functional Outcome after Acute Ischemic Stroke. Journal of the Neurological Sciences, 368, 89-93. &lt;br&gt;https://doi.org/10.1016/j.jns.2016.06.063</mixed-citation></ref><ref id="hanspub.44048-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Dhital, R., Poudel, D.R., Tachamo, N., Gyawali, B., Basnet, S., Shrestha, P. and Karmacharya, P. (2017) Ischemic Stroke and Impact of Thyroid Profile at Presentation: A Systematic Review and Meta-analysis of Observational Studies. Journal of Stroke &amp; Cerebrovascular Diseases, 26, 2926-2934.  
&lt;br&gt;https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.07.015</mixed-citation></ref><ref id="hanspub.44048-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chaker, L., Baumgartner, C., den Elzen, W.P., Collet, T.H., Ikram, M.A., Blum, M.R., Dehghan, A., Drechsler, C., Luben, R.N., Portegies, M.L., Iervasi, G., Medici, M., Stott, D.J., Dullaart, R.P., Ford, I., Bremner, A., Newman, A.B., Wanner, C., Sgarbi, J.A., Dörr, M., Longstreth Jr., W.T., Psaty, B.M., Ferrucci, L., Maciel, R.M., Westendorp, R.G., Jukema, J.W., Ceresini, G., Imaizumi, M., Hofman, A., Bakker, S.J., Franklyn, J.A., Khaw, K.T., Bauer, D.C., Walsh, J.P., Razvi, S., Gussekloo, J., Völzke, H., Franco, O.H., Cappola, A.R., Rodondi, N. and Peeters, R.P. (2016) Thyroid Studies Collaboration. Thyroid Function within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis. Journal of Clinical Endocrinology &amp; Metabolism, 101, 4270-4282.  
&lt;br&gt;https://doi.org/10.1210/jc.2016-2255</mixed-citation></ref><ref id="hanspub.44048-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Li, L.Q., Xu, X.Y., Li, W.Y., Hu, X.Y. and Lv, W. (2019) The Prognostic Value of Total T3 after Acute Cerebral Infarction Is Age-Dependent: A Retrospective Study on 768 Patients. BMC Neurology, 19, Article No. 54.  
&lt;br&gt;https://doi.org/10.1186/s12883-019-1264-z</mixed-citation></ref><ref id="hanspub.44048-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Feng, X., Zhou, X., Yu, F., Liu, Z., Wang, J., Li, Z., Zhan, Q., Yang, Q., Liu, Y. and Xia, J. (2019) Low-Normal Free Triiodothyronine and High Leukocyte Levels in Relation to Stroke Severity and Poor Outcome in Acute Ischemic Stroke with Intracranial Atherosclerotic Stenosis. International Journal of Neuroscience, 129, 635-641.  
&lt;br&gt;https://doi.org/10.1080/00207454.2018.1503179</mixed-citation></ref><ref id="hanspub.44048-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sadana, P., Coughlin, L., Burke, J., Woods, R. and Mdzinarishvili, A. (2015) Anti-Edema Action Ofthyroid Hormone in MCAO Model of Ischemic Brain Stroke: Possible Association with AQP4 Modulation. Journal of the Neurological Sciences, 354, 37-45. &lt;br&gt;https://doi.org/10.1016/j.jns.2015.04.042</mixed-citation></ref><ref id="hanspub.44048-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Badaut, J., Lasbennes, F., Magistretti, P.J. and Regli, L. (2002) Aquaporins in Brain: Distribution, Physiology, and Pathophysiology. Journal of Cerebral Blood Flow &amp; Metabolism, 22, 367-378.  
&lt;br&gt;https://doi.org/10.1097%2F00004647-200204000-00001</mixed-citation></ref><ref id="hanspub.44048-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, S.Y., Leonard, J.L. and Davis, P.J. (2010) Molecular Aspects of Thyroid Hormone Actions. Endocrine Reviews, 31, 139-170. &lt;br&gt;https://doi.org/10.1210/er.2009-0007</mixed-citation></ref><ref id="hanspub.44048-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gorgulu, A., Kins, T., Cobanoglu, S., Unal, F., Izgi, N.I., Yanik, B., et al. (2000) Reduction of Edema and Infarction by Memantine and MK-801 after Focal Cerebral Ischaemia and Reperfusion in Rat. Acta Neurochirurgica, 142, 1287-1292. &lt;br&gt;https://doi.org/10.1007/s007010070027</mixed-citation></ref><ref id="hanspub.44048-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Talhada, D., Feiteiro, J., Costa, A.R., Talhada, T., Cairrão, E., Wieloch, T., Englund, E., Santos, C.R., Gonçalves, I. and Ruscher, K. (2019) Triiodothyronine Modulates Neuronal Plasticity Mechanisms to Enhance Functional Outcome after Stroke. Acta Neuropathologica Communications, 7, Article No. 216. &lt;br&gt;https://doi.org/10.1186/s40478-019-0866-4</mixed-citation></ref><ref id="hanspub.44048-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">de Lange, P., Cioffi, F., Senese, R., Moreno, M., Lombardi, A., Silvestri, E., et al. (2011) Nonthyrotoxic Prevention of Diet-Induced Insulin Resistance by 3,5-diiodo-L-thyronine in Rats. Diabetes, 60, 2730-2739.  
&lt;br&gt;https://doi.org/10.2337/db11-0207</mixed-citation></ref><ref id="hanspub.44048-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Genovese, T., Impellizzeri, D., Ahmad, A., Cornelius, C., Campolo, M., Cuzzocrea, S. and Esposito, E. (2013) Post-Ischaemic Thyroid Hormone Treatment in a Rat Model of Acute Stroke. Brain Research, 1513, 92-102.  
&lt;br&gt;https://doi.org/10.1016/j.brainres.2013.03.001</mixed-citation></ref><ref id="hanspub.44048-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Skvortsova, V.I., Platonova, I.A., Shamalov, N.A., et al. (2016) Clinical and Immunobiochemical Study of Efficacy and Stress-Protective Properties of Thyroliberin at the Acute Stage of Carotid Ischemic Stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, No. s16, 5l-59.</mixed-citation></ref><ref id="hanspub.44048-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sayre, N.L., Sifuentes, M., Holstein, D., Cheng, S.Y., Zhu, X. and Lechleiter, J.D. (2017) Stimulation of Astrocyte Fatty acid Oxidation by Thyroid Hormone Is Protective against Ischemic Stroke-Induced Damage. Journal of Cerebral Blood Flow &amp; Metabolism, 37, 514-527. &lt;br&gt;https://doi.org/10.1177%2F0271678X16629153</mixed-citation></ref><ref id="hanspub.44048-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Talhada, D., Santos, C.R.A., Gonçalves, I. and Ruscher K (2019) Thyroid Hormones in the Brain and Their Impact in Recovery Mechanisms after Stroke. Frontiers in Neurology, 10, Article No. 1103.  
&lt;br&gt;https://doi.org/10.3389/fneur.2019.01103</mixed-citation></ref><ref id="hanspub.44048-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lourbopoulos, A., Mourouzis, I., Karapanayiotides, T., Nousiopoulou, E., Chatzigeorgiou, S., Mavridis, T., et al (2014) Changes in Thyroid Hormone Receptors after Permanent Cerebral Ischemia in Male Rats. Journal of Molecular Neuroscience, 54, 78-91. &lt;br&gt;https://doi.org/10.1007/s12031-014-0253-3</mixed-citation></ref><ref id="hanspub.44048-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Anyetei-Anum, C.S., Roggero, V.R. and Allison, L.A. (2018) Thyroid Hormone Receptor Localizationin Target Tissues. Journal of Endocrinology, 237, R19-R34. &lt;br&gt;https://doi.org/10.1530/JOE-17-0708</mixed-citation></ref><ref id="hanspub.44048-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Carlson, D.J., Strait, K.A., Schwartz, H.L. and Oppenheimer, J.H. (1994) Immunofluorescent Localization of Thyroid Hormone Receptor Isoforms in Glial Cells of Rat Brain. Endocrinology, 135, 1831-1836.  
&lt;br&gt;https://doi.org/10.1210/endo.135.5.7525253</mixed-citation></ref><ref id="hanspub.44048-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Yasuda, R. (2017) Biophysics of Biochemical Signaling in Dendritic Spines: Implications in Synaptic Plasticity. Biophysical Journal, 113, 2152-2159. &lt;br&gt;https://doi.org/10.1016/j.bpj.2017.07.029</mixed-citation></ref><ref id="hanspub.44048-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Brown, C.E., Boyd, J.D. and Murphy, T.H. (2010) Longitudinal in Vivo Imaging Reveals Balanced and Branch-Specific Remodeling of Mature Cortical Pyramidal Dendritic Arbors after Stroke. Journal of Cerebral Blood Flow &amp; Metabolism, 30, 783-791. &lt;br&gt;https://doi.org/10.1038%2Fjcbfm.2009.241</mixed-citation></ref><ref id="hanspub.44048-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Kwon, S.E. and Chapman, E.R. (2011) Synaptophysin Regulates the Kinetics of Synaptic Vesicle Endocytosis in Central Neurons. Neuron, 70, 847-854. &lt;br&gt;https://doi.org/10.1016/j.neuron.2011.04.001</mixed-citation></ref><ref id="hanspub.44048-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Südhof, T.C. (2012) Calcium Control of Neurotransmitter Release. Cold Spring Harbor Perspectives in Biology, 4, Article No. a011353. &lt;br&gt;https://doi.org/10.1101/cshperspect.a011353</mixed-citation></ref><ref id="hanspub.44048-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Südhof, T.C. (2013) A Molecular Machine for Neurotransmitter Release: Synaptotagmin and Beyond. Nature Medicine, 19, 1227-1231. &lt;br&gt;https://doi.org/10.1038/nm.3338</mixed-citation></ref><ref id="hanspub.44048-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Turrigiano, G. (2011) Too Many Cooks? Intrinsic and Synaptic Homeostatic Mechanisms in Cortical Circuit Refinement. Annual Review of Neuroscience, 34, 89-103. &lt;br&gt;https://doi.org/10.1146/annurev-neuro-060909-153238</mixed-citation></ref><ref id="hanspub.44048-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Turrigiano, G. (2012) Homeostatic Synaptic Plasticity: Local and Global Mechanisms for Stabilizing Neuronal Function. Cold Spring Harbor Perspectives in Biology, 4, Article No. a005736. &lt;br&gt;https://doi.org/10.1101/cshperspect.a005736</mixed-citation></ref><ref id="hanspub.44048-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Clarkson, A.N., Overman, J.J., Zhong, S., Mueller, R., Lynch, G. and Carmichael, S.T. (2011) AMPA Receptor-Induced local Brain-Derived Neurotrophic Factor Signaling Mediates Motor Recovery after Stroke. Journal of Neuroscience, 31, 3766-3775. &lt;br&gt;https://doi.org/10.1523/JNEUROSCI.5780-10.2011</mixed-citation></ref><ref id="hanspub.44048-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Isaac, J.T.R., Ashby, M. and McBain, C.J. (2007) The Role of the GluR2 Subunit in AMPA Receptor Function and Synaptic Plasticity. Neuron, 54, 859-871. &lt;br&gt;https://doi.org/10.1016/j.neuron.2007.06.001</mixed-citation></ref><ref id="hanspub.44048-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Seung, H.J., Hyeong, S.C., Ki, J.K., Qing, Z.L. and Sung, K.W. (2009) Electrophysiological Characterization of AMPA and NMDA Receptors in Rat Dorsal Striatum. Korean Journal of Physiology &amp; Pharmacology, 13, 209-214.  
&lt;br&gt;https://doi.org/10.4196/kjpp.2009.13.3.209</mixed-citation></ref><ref id="hanspub.44048-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Losi, G., Garzon, G. and Puia, G. (2008) Nongenomic Regulation of Glutamatergic Neurotransmission in Hippocampus by Thyroid Hormones. Neuroscience, 151, 155-163. &lt;br&gt;https://doi.org/10.1016/j.neuroscience.2007.09.064</mixed-citation></ref><ref id="hanspub.44048-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Boddington, L.J. and Reynolds, J.N.J. (2017) Targeting Interhemispheric Inhibition with Neuromodulation to Enhance Stroke Rehabilitation. Brain Stimulation, 10, 214-222. &lt;br&gt;https://doi.org/10.1016/j.brs.2017.01.006</mixed-citation></ref><ref id="hanspub.44048-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Carmichael, S.T. (2012) Brain Excitability in Stroke: The Yin and Yang of Stroke Progression. Archives of Neurology, 69, 161-167. &lt;br&gt;https://doi.org/10.1001/archneurol.2011.1175</mixed-citation></ref><ref id="hanspub.44048-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Ward, N.S. (2017) Restoring Brain Function after Stroke—Bridging the Gap between Animals and Humans. Nature Reviews Neurology, 13, 244-255. &lt;br&gt;https://doi.org/10.1038/nrneurol.2017.34</mixed-citation></ref><ref id="hanspub.44048-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Alia, C., Spalletti, C., Lai, S., Panarese, A., Micera, S. and Caleo, M. (2016) Reducing GABA A-Mediated Inhibition Improves Forelimb Motor Function after Focal Cortical Stroke in Mice. Scientific Reports, 29, Article No. 37823.  
&lt;br&gt;https://doi.org/10.1038/srep37823</mixed-citation></ref><ref id="hanspub.44048-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Clarkson, A.N., Huang, B.S., Macisaac, S.E., Mody, I. and Carmichael, S.T. (2010) Reducing Excessive GABA-Mediated Tonic Inhibition Promotes Functional Recovery after Stroke. Nature, 468, 305-309.  
&lt;br&gt;https://doi.org/10.1038/nature09511</mixed-citation></ref><ref id="hanspub.44048-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Zeiler, S.R., Gibson, E.M., Hoesch, R.E., Li, M.Y., Worley, P.F., O’Brien, R.J., et al. (2013) Medial Premotor Cortex Shows a Reduction in Inhibitory Markers and Mediates Recovery in a Mouse Model of Focal Stroke. Stroke, 44, 483-489. &lt;br&gt;https://doi.org/10.1161/STROKEAHA.112.676940</mixed-citation></ref><ref id="hanspub.44048-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Sammali, E., Alia, C., Vegliante, G., Colombo, V., Giordano, N., Pischiutta, F., et al. (2017) Intravenous Infusion of Human Bone Marrow Mesenchymal Stromal Cells Promotes Functional Recovery and Neuroplasticity after Ischemic Stroke in Mice. Scientific Reports, 7, Article No. 6962. &lt;br&gt;https://doi.org/10.1038/s41598-017-07274-w</mixed-citation></ref><ref id="hanspub.44048-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Mokhtari, T., Akbari, M., Malek, F., Kashani, I.R., Rastegar, T., Noorbakhsh, F., Ghazi-Khansari, M., Attari, F. and Hassanzadeh, G. (2017) Improvement of Memory and Learning by Intracerebroventricular Microinjection of T3 in Rat Model of Ischemic Brain Stroke Mediated by Upregulation of BDNF and GDNF in CA1 Hippocampal Region. DARU Journal of Pharmaceutical Sciences, 25, Article No. 4. &lt;br&gt;https://doi.org/10.1186/s40199-017-0169-x</mixed-citation></ref><ref id="hanspub.44048-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Sutherland, B.A., Neuhaus, A.A., Couch, Y., Balami, J.S., DeLuca, G.C., Hadley, G., et al. (2016) The Transient Intraluminal Filament Middle Cerebral Artery Occlusion Model as a Model of Endovascular Thrombectomy in Stroke. Journal of Cerebral Blood Flow &amp; Metabolism, 36, 363-369. &lt;br&gt;https://doi.org/10.1177%2F0271678X15606722</mixed-citation></ref><ref id="hanspub.44048-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Shahjouei, S., Cai, P.Y., Ansari, S., Sharififar, S., Azari, H., Ganji, S., et al. (2016) Middle Cerebral Artery Occlusion Model of Stroke in Rodents. Journal of Vascular and Inter-Ventional Neurology, 8, 1-8.</mixed-citation></ref><ref id="hanspub.44048-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Erfani, S., Khaksari, M., Oryan, S., Shamsaei, N., Aboutaleb, N., Nikbakht, F., et al. (2015) Visfatin Reduces Hippocampal CA1 Cells Death and Improves Learning and Memory Deficits after Transient Global Ischemia/Reperfusion. Neuropeptides, 49, 63-68. &lt;br&gt;https://doi.org/10.1016/j.npep.2014.12.004</mixed-citation></ref><ref id="hanspub.44048-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Chen, A., Xiong, L.-J., Tong, Y. and Mao, M. (2013) The Neuroprotective Roles of BDNF in Hypoxic Ischemic Brain Injury (Review). Biomedical Reports, 1, 167-176. &lt;br&gt;https://doi.org/10.3892/br.2012.48</mixed-citation></ref><ref id="hanspub.44048-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Duarte, E.P., Curcio, M., Canzoniero, L.M. and Duarte, C.B. (2012) Neuroprotection by GDNF in the Ischemic Brain. Growth Factors, 30, 242-257. &lt;br&gt;https://doi.org/10.3109/08977194.2012.691478</mixed-citation></ref><ref id="hanspub.44048-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Sui, L., Ren, W.-W. and Li, B.-M. (2010) Administration of Thyroid Hormone Increases Reelin and Brain-Derived Neurotrophic Factor Expression in Rat Hippocampus in Vivo. Brain Research, 1313, 9-24.  
&lt;br&gt;https://doi.org/10.1016/j.brainres.2009.12.010</mixed-citation></ref><ref id="hanspub.44048-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Campolo, M., Genovese, T., Impellizzeri, D., Ahmad, A., Cornelius, C., Cuzzocrea, S., et al. (2013) Post-Ischemic Thyroid Hormone Treatment in a Rat Model of Acute Stroke. The FASEB Journal, 27, 662.17.  
&lt;br&gt;https://doi.org/10.1096/fasebj.27.1_supplement.662.17</mixed-citation></ref><ref id="hanspub.44048-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Davis, P.J. (2011) Integrated Nongenomic and Genomic Actions of Thyroid Hormone on Blood Vessels. Current Opinion in Endocrinology &amp; Diabetes and Obesity, 18, 293-294. &lt;br&gt;https://doi.org/10.1097/MED.0b013e32834abeb2</mixed-citation></ref><ref id="hanspub.44048-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y. and Meyer, M.A. (2010) Clinical Analysis on Alteration of Thyroid Hormones in the Serum of Patients with Acute Ischemic Stroke. Stroke Research and Treatment, 2010, Article ID: 290678.  
&lt;br&gt;https://doi.org/10.4061/2010/290678</mixed-citation></ref><ref id="hanspub.44048-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Hiroi, Y., Kim, H.-H., Ying, H., Furuya, F., Huang, Z., Simoncini, T., et al. (2006) Rapid Nongenomic Actions of Thyroid Hormone. Proceedings of the National Academy of Sciences of the United States of America, 103, 14104-14109.  
&lt;br&gt;https://doi.org/10.1073/pnas.0601600103</mixed-citation></ref><ref id="hanspub.44048-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Lin, H.-Y., Davis, F.B., Luidens, M.K., Mousa, S.A., Cao, J.H., Zhou, M., et al. (2011) Molecular Basis for Certain Neuroprotective Effects of Thyroid Hormone. Frontiers in Molecular Neuroscience, 4, Article No. 29.  
&lt;br&gt;https://doi.org/10.3389/fnmol.2011.00029</mixed-citation></ref></ref-list></back></article>